VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced that Abstract #1405, Reduction in Cardiovascular Risk Factors in Obese Adults Treated With Topiramate Plus Phentermine was presented on October 9, 2007 by its author, Dr. Kishore M. Gadde, at the 7th International Congress on Coronary Artery Disease (ICCAD) Conference in Venice, Italy. The abstract concludes that obese patients treated for 24 weeks with Qnexa, an investigational drug, had improvements in blood pressure, triglycerides, total cholesterol, and C-reactive protein.
The primary objective of the study was to evaluate changes in body weight. The weight loss data from this study had been previously reported. Dr. Gadde's poster presentation focused on the cardiovascular outcomes of patients in the study; specifically, changes in blood pressure (BP), lipids and C-reactive protein (CRP). Two hundred obese patients (mean BMI of 38.6) were randomly assigned to placebo (PBO), phentermine (PHN), topiramate (TPM), or Qnexa for 24 weeks. The results showed that mean changes in body weight (kg) for placebo, phentermine, topiramate, and Qnexa were reductions of 2.2, 5.3, 6.6, and 11.4, respectively (p less than 0.0001).
The primary objective of the study was to evaluate changes in body weight. The weight loss data from this study had been previously reported. Dr. Gadde's poster presentation focused on the cardiovascular outcomes of patients in the study; specifically, changes in blood pressure (BP), lipids and C-reactive protein (CRP). Two hundred obese patients (mean BMI of 38.6) were randomly assigned to placebo (PBO), phentermine (PHN), topiramate (TPM), or Qnexa for 24 weeks. The results showed that mean changes in body weight (kg) for placebo, phentermine, topiramate, and Qnexa were reductions of 2.2, 5.3, 6.6, and 11.4, respectively (p less than 0.0001).